TY - JOUR
T1 - The Affordability of Providing Sexually Transmitted Disease Services at a Safety-net Clinic
AU - Dean, Lorraine T.
AU - Montgomery, Madeline C.
AU - Raifman, Julia
AU - Nunn, Amy
AU - Bertrand, Thomas
AU - Almonte, Alexi
AU - Chan, Philip A.
N1 - Funding Information:
Dr. Dean is supported by the National Cancer Institute grants K01CA184288 and (Sidney Kimmel Cancer Center) P30CA006973; and National Institute of Allergy and Infectious Disease grant (Johns Hopkins University Center for AIDS Research) P30AI094189. Drs. Dean, Raifman, and Nunn are supported by the National Institute of Mental Health grant R25MH083620. Dr. Chan is supported by the National Institute on Drug Abuse grant R34DA042648, and National Institutes of Mental Health grants R34MH110369, R34MH109371, R21MH113431, and R21MH109360.
Publisher Copyright:
© 2018 American Journal of Preventive Medicine
PY - 2018/4
Y1 - 2018/4
N2 - Introduction: Sexually transmitted diseases continue to increase in the U.S. There is a growing need for financially viable models to ensure the longevity of safety-net sexually transmitted disease clinics, which provide testing and treatment to high-risk populations. This micro-costing analysis estimated the number of visits required to balance cost and revenue of a sexually transmitted disease clinic in a Medicaid expansion state. Methods: In 2017, actual and projected cost and revenues were estimated from the Rhode Island sexually transmitted disease clinic in 2015. Projected revenues for a hypothetical clinic offering a standard set of sexually transmitted disease services were based on Medicaid; private (“commercial”) insurance; and institutional (“list price”) reimbursement rates. The number of visits needed to cover clinic costs at each rate was assessed. Results: Total operating cost for 2,153 clinic visits was estimated at $255,769, or $119 per visit. Laboratory testing and salaries each accounted for 44% of operating costs, medications for treatment 7%, supplies 5%, and 28% of visits used insurance. For a standard clinic offering a basic set of sexually transmitted disease services to break even, a projected 73% of visits need to be covered at the Medicaid rate, 38% at private rate, or 11% at institutional rate. Conclusions: Sexually transmitted disease clinics may be financially viable when a majority of visits are billed at a Medicaid rate; however, mixed private/public models may be needed if not all visits are billed. In this manner, sexually transmitted disease clinics can be solvent even if not all visits are billed to insurance, thus ensuring access to uninsured or underinsured patients.
AB - Introduction: Sexually transmitted diseases continue to increase in the U.S. There is a growing need for financially viable models to ensure the longevity of safety-net sexually transmitted disease clinics, which provide testing and treatment to high-risk populations. This micro-costing analysis estimated the number of visits required to balance cost and revenue of a sexually transmitted disease clinic in a Medicaid expansion state. Methods: In 2017, actual and projected cost and revenues were estimated from the Rhode Island sexually transmitted disease clinic in 2015. Projected revenues for a hypothetical clinic offering a standard set of sexually transmitted disease services were based on Medicaid; private (“commercial”) insurance; and institutional (“list price”) reimbursement rates. The number of visits needed to cover clinic costs at each rate was assessed. Results: Total operating cost for 2,153 clinic visits was estimated at $255,769, or $119 per visit. Laboratory testing and salaries each accounted for 44% of operating costs, medications for treatment 7%, supplies 5%, and 28% of visits used insurance. For a standard clinic offering a basic set of sexually transmitted disease services to break even, a projected 73% of visits need to be covered at the Medicaid rate, 38% at private rate, or 11% at institutional rate. Conclusions: Sexually transmitted disease clinics may be financially viable when a majority of visits are billed at a Medicaid rate; however, mixed private/public models may be needed if not all visits are billed. In this manner, sexually transmitted disease clinics can be solvent even if not all visits are billed to insurance, thus ensuring access to uninsured or underinsured patients.
UR - http://www.scopus.com/inward/record.url?scp=85041572182&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041572182&partnerID=8YFLogxK
U2 - 10.1016/j.amepre.2017.12.016
DO - 10.1016/j.amepre.2017.12.016
M3 - Article
C2 - 29397280
AN - SCOPUS:85041572182
SN - 0749-3797
VL - 54
SP - 552
EP - 558
JO - American Journal of Preventive Medicine
JF - American Journal of Preventive Medicine
IS - 4
ER -